InnoVoyce

Executive Summary

InnoVoyce is a US-based medical technology company commercializing the VYLO™ 455nm blue light solid-state laser for precision soft tissue surgery. Its initial FDA-cleared indication targets ENT and voice health disorders, leveraging a compact, efficient laser platform with a portfolio of complementary fibers and accessories. The technology offers superior hemostasis and reduced thermal damage compared to traditional lasers, positioning it as a disruptive tool in outpatient and ambulatory surgical settings. With FDA clearance achieved, the company is now focused on commercial launch and market adoption, targeting the large and growing ENT surgical market. While financial details remain undisclosed, InnoVoyce's validated technology and clear regulatory pathway suggest meaningful potential in the surgical laser landscape. Future expansion into additional surgical specialties could further enhance its addressable market, though near-term revenue growth hinges on successful commercial execution and clinician adoption.

Upcoming Catalysts (preview)

• Q3 2026Initial commercial adoption and key opinion leader feedback in ENT surgeries70% success
• Q4 2026FDA 510(k) clearance for expanded indications (e.g., gynecology, urology)50% success
• Q2 2026Strategic distribution partnership with a major medical device company40% success